BioSpace News Archive

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2021 financial results after the market closes on Monday, August 9, 2021.

Rallybio Corporation (Nasdaq: RLYB), today announced the closing of its initial public offering of 7,130,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 930,000 additional shares of common stock, at a public offering price of $13.00 per share.

Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its second quarter 2021 financial results on Monday, August 9, 2021.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that company management will participate in the following upcoming investor events and conferences:

Oyster Point Pharma, Inc. announced that the Compensation Committee of its Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 93,600 shares of common stock to 58 new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.

TYME Technologies, Inc., an emerging biotechnology company developing cancer metabolism-based therapies, announced that the Company will report its first quarter 2022 financial results on Tuesday, August 10, 2021 at 8:30 AM ET.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study “Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,"(1) in Clinical Cancer Research, a journal published by the American Association for Cancer Research.

Bruker Corporation announced financial results for its second quarter and for the six months ended June 30, 2021.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, August 9, 2021 at 4:30 p.m.